• 대한수의학회지
• /
• 제38권2호
• /
• pp.366-370
• /
• 1998

7일령의 송아지 4마리에 실험적으로 크립토스포리디움을 감염시키고 면역혈청, 면역초유 그리고 단크론항체(C6)을 투여하여 이들의 면역요법제로서의 효과를 측정하였다. 크립토스포리디움 감염후 4일째부터 3일간 하루 2회(200~500ml)씩 3종의 면역요법제를 송아지 1마리씩 각각 경구로 투여하였으며, 나머지 한마리의 대조송아지에는 인산 완충액을 경구로 투여하였다. 크립토스포리디움에 감염된 송아지들은 설사를 나타냈는데 대조송아지의 경우 감염후 3일째부터 9일간 설사증상을 나타냈다. 면역혈청, 면역초유 그리고 C6로 치료한 송아지들은 치료후 각각 3일, 2일, 5일째부터 정상에 가까운 분변을 배출하기 시작하였다. 면역혈청과 면역초유로 치료한 송아지들의 경우, 분변으로 배출되는 오시스트의 수가 대조송아지에 비해 현저하게 줄어들었다. 이러한 결과들은 실험에 제공된 면역요법제중 면역초유나 면역혈청이 크립토스포리디움에 감염된 송아지의 설사증상과 오시스트의 배출을 억제하는 효과가 있음을 나타내는 것이다.

• 한국축산식품학회지
• /
• 제37권1호
• /
• pp.1-9
• /
• 2017

The rotavirus-induced diarrhea of human and animal neonates is a major public health concern worldwide. Until recently, no effective therapy is available to specifically inactivate the rotavirion particles within the gut. Passive immunotherapy by oral administration of chicken egg yolk antibody (IgY) has emerged of late as a fresh alternative strategy to control infectious diseases of the alimentary tract and has been applied in the treatment of diarrhea due to rotavirus infection. The purpose of this concise review is to evaluate evidence on the properties and performance of anti-rotavirus immunoglobulin Y (IgY) for prevention and treatment of rotavirus diarrhea in human and animal neonates. A survey of relevant anti-rotavirus IgY basic studies and clinical trials among neonatal animals (since 1994-2015) and humans (since 1982-2015) have been reviewed and briefly summarized. Our analysis of a number of rotavirus investigations involving animal and human clinical trials revealed that anti-rotavirus IgY significantly reduced the severity of clinical manifestation of diarrhea among IgY-treated subjects relative to a corresponding control or placebo group. The accumulated information as a whole depicts oral IgY to be a safe and efficacious option for treatment of rotavirus diarrhea in neonates. There is however a clear need for more randomized, placebo controlled and double-blind trials with bigger sample size to further solidify and confirm claims of efficacy and safety in controlling diarrhea caused by rotavirus infection especially among human infants with health issues such as low birth weights or compromised immunity in whom it is most needed.